Study Overview

The ACCORD Renal Ancillary Study is a research protocol designed to examine possible mechanisms linked to the elevation in serum creatinine among diabetic participants treated with fenofibrate and placebo. Participants in the ACCORD Lipid Trial who are on blinded medication at entry to the end of study visit and who did or did not experience specified changes in serum creatinine upon initiation of blinded medication will be eligible for this ancillary study. Information on participant eligibility is available on the participant-specific background information page of the main study website.

Back to Login Screen >>